ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / QGEN / forecast
TWST (47) RGEN (61) KYMR (51) KRYS (73) ⌘ Pro Terminal →

Qiagen N.V. (QGEN) 12-Month Stock Forecast & Price Target Cone

$50.35 +0.26% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $50.49

Qiagen N.V. (QGEN) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (62.2% gross margin, 8% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $10.35B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on QGEN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is QGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Qiagen N.V. (NYSE: QGEN) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $50.35 (+0.26% 1D, market cap $10.35B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, QGEN ranks #59 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does QGEN compare to TWST and RGEN in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), QGEN carries a Roarable B (72/100 RQD), trailing P/E of 24.4x, gross margin of 62.2%, and ROIC of 8.0%. By comparison, TWST (Twist Bioscience Corporation) holds a D grade (47/100 RQD, P/E N/A, ROIC -11.7%, cap $10.13B) and RGEN (Repligen Corporation) posts a C- grade (61/100 RQD, P/E N/A, ROIC 2.3%, cap $10.03B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for QGEN?
▼

Per QGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001015820), Qiagen N.V. generated $2.09B in revenue (+5.7% YoY), $424.9M in net income, and $453.3M in free cash flow against $6.28B in total assets and $1.65B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $50.50 (+0.29%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 21.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B
Cash (11)Whales (17)SEC (16)Macro (13)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$63 Bull$54 Base$41 Bear
📬 FREE QGEN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QGEN)Realized 20D OHLCV Swing Band: ±4%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY QGEN SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+17/20 pts (24% of score)

20D Institutional Volume Accumulation (±4% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 3.54 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9

▼ #1 Drag / Risk Factor: Cash Engine Quality11/20 pts (-9 pt drag)

Capital intensity & 22.3% operating margin leave 9 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$45.56+9.7% Next Q
Q2 (-2Q)
67
Grade B-$50.00+0.7% Next Q
Q3 (-1Q)
69
Grade B-$50.33+0% Next Q
Current
72
Grade B$50.35+7% Hist 90D α
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the QGEN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, QGEN faces multiple-compression risk if 24.4x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($45.54) or 200D SMA ($42.59) invalidates the momentum regime and cuts Target Base ($53.52) toward Bear Floor ($41.29).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $QGEN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QGEN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your QGEN Position Size: $10,000

Shares at $50.35: 198.6 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $41.29
$8,201
$-1,799 (-18.0%)
12M Consensus BaseTarget $53.52
$10,630
+$630 (+6.3%)
12M Bull Case BreakoutTarget $63.15
$12,542
+$2,542 (+25.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (34 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 23● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskOUTPERFORM$5674%A
Goldman SachsSector Coverage LeadBUY$5969%B
JP MorganUS Large-Cap ResearchHOLD$4758%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (QGEN Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
QGEN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +48.26%▲ ASCENDING CHANNEL
2026-11-03O $50.34H $50.35L $50.22C $50.35VOL 4.17M
RES: $52.79SUP: $42.60SMA50: $45.54SMA200: $42.59
$52.10$46.80$41.49$36.19$30.88RES $52.79SUP $42.60$50.352026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

QGEN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 QGEN Butterfly Map → + Track QGEN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
18.1%/yr Implied 5Y Growth

vs. +5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on QGEN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for QGEN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QGEN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QGEN)

Health Care Rank #59 of 1015 ⚔️ TWST vs QGEN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (QGEN vs. TWST, RGEN, KYMR, KRYS)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Qiagen N.V. (QGEN) ranks #59 by composite RQD confidence (72/100, grade B) and #106 by equity capitalization ($10.35B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently holds the highest overall quantitative score in the immediate peer group at 73/100 (B) compared with QGEN at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
QGEN ACTIVE
Qiagen N.V.
B 72/100 24.4x 62.2% 8.0% +0.26% $10.35B Benchmark Subject
TWST
Twist Bioscience Corporation
D 47/100 — 94.2% -11.7% -15.54% $10.13B /twst-vs-qgen →
RGEN
Repligen Corporation
C- 61/100 — 88.2% 2.3% -2.25% $10.03B /rgen-vs-qgen →
KYMR
Kymera Therapeutics Inc.
D 51/100 32.7x — -21.4% +0.70% $10.81B /kymr-vs-qgen →
KRYS
Krystal Biotech Inc.
B 73/100 46.9x — 16.5% -10.95% $9.84B /krys-vs-qgen →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001015820 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Qiagen N.V. (QGEN) reported GAAP revenue of $2.09B (+5.7% vs. FY2024 revenue of $1.98B , and +6.3% cumulative change since FY2023) , GAAP net income of $424.9M, operating cash flow of $654.3M, and free cash flow of $453.3M (-10.5% YoY). On the balance sheet, QGEN closed FY2025 with $6.28B in total assets against $1.65B in total debt (Altman Z-Score: 3.54, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.09B $424.9M $654.3M $453.3M $6.28B $1.65B
FY2024 (FY) 2024-12-31 $1.98B $83.6M $673.6M $506.4M $5.69B $839.7M
FY2023 (FY) 2023-12-31 $1.97B $341.3M $459.5M $371.0M $5.71B $1.34B

3. QGEN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is QGEN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Qiagen N.V. (NYSE: QGEN) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $50.35 (+0.26% 1D, market cap $10.35B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 17/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, QGEN ranks #59 in composite RQD confidence.

How does QGEN compare to TWST and RGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), QGEN carries a Roarable B (72/100 RQD), trailing P/E of 24.4x, gross margin of 62.2%, and ROIC of 8.0%. By comparison, TWST (Twist Bioscience Corporation) holds a D grade (47/100 RQD, P/E N/A, ROIC -11.7%, cap $10.13B) and RGEN (Repligen Corporation) posts a C- grade (61/100 RQD, P/E N/A, ROIC 2.3%, cap $10.03B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for QGEN?

Per QGEN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001015820), Qiagen N.V. generated $2.09B in revenue (+5.7% YoY), $424.9M in net income, and $453.3M in free cash flow against $6.28B in total assets and $1.65B in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is QGEN trading relative to its 50-day, 200-day, and 52-week technical levels?

QGEN last traded at $50.35 (+0.26% on volume of 3,572,479 shares), positioning the stock +10.56% above its 50-day simple moving average ($45.54) and +18.22% above its 200-day simple moving average ($42.59). Across its 52-week range of $32.53 to $57.82, QGEN sits at the 70.5% percentile with a 14-day RSI of 71.0 (OVERBOUGHT (>70)) and an implied next-earnings move of ±4.0% ($48.34 to $52.36).

Direct Sub-Reports: QGEN RQD Cockpit QGEN 12M Forecast QGEN Earnings & Move QGEN Dividends & DRIP QGEN Insiders & 13F QGEN Whale Options QGEN Profit Sankey QGEN News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ SEC XBRL & RQD VERIFIED

QGEN — Qiagen N.V.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Qiagen N.V. (QGEN) earns a live Roarable RQD composite score of 72/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $50.35 (+0.26% 1D, market capitalization $10.35B).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 8.0%, gross margin of 62.2%, operating margin of 22.3%, and free cash flow yield of 4.37%.
  • Whale 13F & Options Flow (17/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (16/20): Incorporates a 0.95x equity beta, Altman Z-Score of 3.54, Piotroski F-Score of 9/9, and Debt/Equity of 0.44x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Qiagen N.V. (QGEN) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The company reported revenue of $2.09B for FY 2025. — for product lines, customer base, or detailed revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Qiagen N.V. (QGEN) reported $2.09B in annual revenue (up from $1.98B in FY2024, +5.7% YoY) and $424.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.97B revenue, $341.3M net income) through FY2025, QGEN scaled operating cash flow to $654.3M and free cash flow to $453.3M, backed by $6.28B in total assets against $1.65B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 72/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 17/20, sustained execution supports upside toward the upper end of the $32.53 – $57.82 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 24.4x trailing P/E and 17.6x EV/EBITDA against 22.3% operating margins and a 0.95x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

— The Butterfly Supply-Chain Graph reports no supply-chain relationships and no proprietary signals, so upstream/downstream dependencies and sector correlations cannot be assessed from the provided data. For an investor, the most material second-order question is how the takeover-related news flow, if confirmed, would alter the shares' sensitivity to the sector and market factors reflected in the Beta of 0.95.

  • Key Question #1: Can QGEN sustain or expand its 22.3% operating margin and 8.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.09B and free cash flow of $453.3M, how will capital allocation balance growth reinvestment against $1.65B in total debt?
  • Key Question #3: How sensitive is QGEN's 22.7x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.95x)?

QGEN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Qiagen N.V. (QGEN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to QGEN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

QGEN Bull vs. Bear Conversation Board — What's Your Call at $50.35?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON QGEN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on QGEN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $58.26 (+16.0%)
📌 Pinned Debate

The Forensic Balance Sheet pillar scores 16 of 20 with a Piotroski F-Score of 9/9 and Altman Z of 3.54, while institutional flow and ta

Picked up a starter position in QGEN in my $100K Virtual Cash book at $50.22. The Forensic Balance Sheet pillar scores 16 of 20 with a Piotroski F-Score of 9/9 and Altman Z of 3.54, while institutional flow and takeover-related catalysts add upside optionality.. Trading inside a $32.53–$57.82 52-week range with 4.37% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

RetailWhale_TX 🐂 BULL

@CreditSpread_Watch Shorting a 17/20 institutional whale-flow stock at $50.22 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $42.18 (-16.0%)
Spot @ $50.22

ROIC of 8% and a 4.37% FCF yield are modest, debt rose to $1.65B in FY 2025, and the stock trades at 24.4x TTM earnings.

Careful chasing QGEN at $50.22. ROIC of 8% and a 4.37% FCF yield are modest, debt rose to $1.65B in FY 2025, and the stock trades at 24.4x TTM earnings.. Gross margin is 62.2%, but operating margin is 22.3%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $42.18 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%